Omnicell, Inc.
NASDAQ•OMCL
CEO: Mr. Randall A. Lipps
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Listing Date: 2001-08-09
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Contact Information
Market Cap
$2.31B
P/E (TTM)
116.9
47.3
Dividend Yield
--
52W High
$55.00
52W Low
$22.66
52W Range
Rank31Top 21.6%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$310.63M+9.99%
4-Quarter Trend
EPS
$0.12-36.84%
4-Quarter Trend
FCF
$18.51M+96.58%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenues reached $870.9 M USD, growing 8% for nine months. Gross profit increased 13% to $373.1 M USD.
Profitability Turnaround Swung to net income of $4.1 M USD for nine months, compared to $3.3 M USD loss previous period. Gross margin improved to 43%.
Strong Service Revenue Service revenues grew 8% to $385.0 M USD for nine months, driven by technical and SaaS/Expert Services demand.
Debt Reduction Activity Repaid $175.0 M USD principal balance of 2025 Convertible Senior Notes upon maturity in September 2025.
Risk Factors
International Sales Risks International operations face risks from reliance on distributors, managing foreign regulations, and currency fluctuations.
Supply Chain Cost Pressures Product costs impacted by potential price fluctuations, shortages of raw materials, and semiconductor chip supply requirements.
Capital Expenditure Demand Significant capital expenditure required for system modernization and automation adoption by healthcare facilities remains a risk.
Trade Restriction Uncertainty Ongoing US trade restrictions, tariffs, and potential retaliation create uncertainty impacting supply chain and cost forecasts.
Outlook
Autonomous Pharmacy Vision Strategy focuses on advancing Autonomous Pharmacy vision through robotics, smart devices, and workflow optimization investments.
Growth in Ambulatory Care Expect growth opportunities in Ambulatory Care, driven by retail pharmacy expansion and value-based care adoption trends.
Specialty Pharmacy Expansion Continued investment in Specialty Pharmacy and 340B Program solutions targeting complex condition medication management.
Liquidity Position Maintained Existing cash, operating cash flows, and $350.0 M USD available credit facility expected to fund needs for twelve months.
Peer Comparison
Revenue (TTM)
$2.90B
TDOC$2.53B
CLOV$1.77B
Gross Margin (Latest Quarter)
GDRX93.2%
TDOC70.1%
68.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TXG | $2.83B | -36.8 | -10.3% | 8.5% |
| OMCL | $2.31B | 116.9 | 1.6% | 10.6% |
| ASTH | $1.36B | 140.1 | 1.3% | 48.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.4%
Moderate Growth
4Q Net Income CAGR
-29.9%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 5, 2026
EPS:$0.47
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 5, 2025|Revenue: $310.63M+10.0%|EPS: $0.12-36.8%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 6, 2025|Revenue: $290.56M+5.0%|EPS: $0.12+47.6%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 7, 2025|Revenue: $269.67M+9.6%|EPS: $-0.15-55.9%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 27, 2025|Revenue: $1.11B-3.0%|EPS: $0.27+160.0%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 8, 2024|Revenue: $282.42M-5.4%|EPS: $0.19+58.3%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 6, 2024|Revenue: $276.79M-7.4%|EPS: $0.08+6.3%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 7, 2024|Revenue: $246.15M-15.3%|EPS: $-0.34+3.0%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 28, 2024|Revenue: $1.15B-11.5%|EPS: $-0.45-446.2%Miss